A method for rapidly identifying radix kadsurae and preparations thereof
The test solution was prepared by using anhydrous ethanol and ethyl acetate solvent system, developed on silica gel G thin-layer plate and examined under ultraviolet light. This method solves the problems of environmental pollution and inaccurate identification caused by the use of toxic solvents in the prior art, and realizes rapid, safe and specific identification of Zanthoxylum nitidum and its preparations.
Patent Information
- Application Number
- CN202310888063.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-19
- Publication Date
- 2025-12-19
- Estimated Expiration
- 2043-07-19
AI Technical Summary
In the existing technology, the identification methods for Zanthoxylum nitidum and its preparations use highly toxic organic solvents, which lead to environmental pollution and harm to the experimenters, and fail to specifically identify its lipid-soluble effective parts.
The test solution was prepared by using a combination of anhydrous ethanol and ethyl acetate as solvents, followed by ultrasonic treatment and centrifugation. The solution was then developed on silica gel G thin-layer plates, and the fluorescent spots were examined under ultraviolet light for identification. This method avoids the use of toxic solvents such as chloroform and specifically identifies the lipid-soluble effective fractions of Zanthoxylum nitidum and its preparations.
It enables rapid, safe, and specific identification of Zanthoxylum nitidum medicinal materials and their preparations, reduces environmental pollution and human harm, meets the requirements of modern Chinese medicine quality control, and improves identification efficiency and accuracy.
Smart Images

Figure HDA0004346963170000011 
Figure HDA0004346963170000021 
Figure HDA0004346963170000031
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to a thin layer identification method of traditional Chinese medicine, in particular to a rapid identification method of Zanthoxylum nitidum (Roxb.) DC and its preparations. BACKGROUND
[0002] The quality standard of Zanthoxylum nitidum (Roxb.) DC is recorded in Chinese Pharmacopoeia, which is the dried root of Zanthoxylum nitidum (Roxb.) DC of Rutaceae, one of the ten medicinal materials in Guangxi, also known as "Ruodijinniu", "Shanjiao", "Xiashantuhu", etc., mainly produced in Guangxi, bitter and hot in nature, and has been clinically used for more than two thousand years, especially widely used in Guangxi folk and clinic, and the Zhuang medicine believes that Zanthoxylum nitidum has the functions of dredging fire and dragon channels, expelling wind and toxin, clearing heat and toxin, and relieving swelling and pain, and is used for treating various pains such as "Fangwang" (rheumatic pain) and "Huiyin" (lumbago).
[0003] In the 1960s and 1970s, in order to solve the problem of lack of doctors and medicine, Guangxi Baiyunshan Yingkang Pharmaceutical Co., Ltd. organized Zhuang medicine experts to conduct medicine investigation and sorting in various counties and cities in Guangxi, and deeply explored Zhuang and Yao medicine and other folk prescriptions, and found that Zanthoxylum nitidum, red fish eye, nine-layer wind, mountain wind, three-leaf green vine, and three-leaf saptide were used to treat rheumatic diseases in places where Zhuang people lived. The prescription has been passed down from generation to generation in the Zhuang area for a long time, and has been used for a long time, with significant curative effect. Zhuang medicine experts conducted in-depth research and verification on the prescription, and conducted research on traditional Chinese medicine preparations, pharmacology, and toxicology, and through clinical research in many hospitals, the total effective rate was 87.3%, which proved that the drug was safe and effective, and finally developed Zhuang medicine preparation Huatuo Fengtongbao tablets (originally named Fengshiling tablets) and Huatuo Fengtongbao capsules (originally named Fengshiling capsules) with Zanthoxylum nitidum as the main component, which had good therapeutic effect on joint swelling and pain, deformation, rheumatoid arthritis, periarthritis of shoulder, and rheumatoid arthritis; at the same time, Zhuang medicine experts in Guangxi refined and extracted effective parts of Zanthoxylum nitidum according to the experience of Zhuang folk medicine, and through modern pharmacological and toxicological tests, the test results showed that Zanthoxylum nitidum had good antispasmodic, analgesic, and sedative effects, and through clinical verification in 16 domestic hospitals, the total effective rate was 83.9%, which proved that the drug was safe and effective, and finally developed Zanthoxylum nitidum analgesic tablets (originally named Zanthoxylum nitidum N4 analgesic tablets) as a single prescription of pure Zhuang medicine, which had curative effect on pain caused by ulcer, intestinal spasm, cholecystitis, liver cancer, etc.
[0004] At present, the identification of Zanthoxylum nitidum (Roxb.) DC. medicinal materials in Chinese Pharmacopoeia, and the identification of Zanthoxylum nitidum (Roxb.) DC. medicinal materials in current national drug standards of Huatuo Fengtongbao tablets, Huatuo Fengtongbao capsules and Zanthoxylum nitidum (Roxb.) DC. analgesic tablets all use toxic chloroform, benzene and other organic solvents, which pollute the environment and harm the human body, and the identification methods are not specific to the fat-soluble effective parts of Zanthoxylum nitidum (Roxb.) DC. and its preparations, and are one-sided. Therefore, in view of the defects of the prior art, a rapid identification method for Zanthoxylum nitidum (Roxb.) DC. medicinal materials and its preparations is urgently needed. SUMMARY
[0005] The purpose of the present application is to provide a rapid identification method for Zanthoxylum nitidum (Roxb.) DC. medicinal materials and its preparations in view of the defects of the prior art. The identification method can reduce harm to the human body and environmental pollution, and can specifically and rapidly identify the effective parts of Zanthoxylum nitidum (Roxb.) DC. and its preparations.
[0006] In order to achieve the above purpose of the present application, the following technical solutions are adopted:
[0007] A rapid identification method for Zanthoxylum nitidum (Roxb.) DC. medicinal materials and its preparations, wherein the preparation is a Zanthoxylum nitidum (Roxb.) DC. containing Huatuo Fengtongbao tablet, Huatuo Fengtongbao capsule, Zanthoxylum nitidum (Roxb.) DC. analgesic tablet and other Zanthoxylum nitidum (Roxb.) DC. medicinal materials, and the method comprises the following steps:
[0008] (1) 0.5 g of Zanthoxylum nitidum (Roxb.) DC. reference medicinal materials is added with 20 ml of anhydrous ethanol, ultrasonic treatment is performed for 10 min, filtration is performed, the residue of the filtrate is dried by evaporation, 5 ml of ethyl acetate is added, ultrasonic treatment is performed for 5 min, centrifugation is performed, and the supernatant is taken as the Zanthoxylum nitidum (Roxb.) DC. reference medicinal material solution;
[0009] (2) 0.5 g of Zanthoxylum nitidum (Roxb.) DC. medicinal material powder is added with 20 ml of anhydrous ethanol, ultrasonic treatment is performed for 10 min, filtration is performed, the residue of the filtrate is dried by evaporation, 5 ml of ethyl acetate is added, ultrasonic treatment is performed for 5 min, centrifugation is performed, and the supernatant is taken as the Zanthoxylum nitidum (Roxb.) DC. medicinal material test solution;
[0010] (3) 10 tablets of Huatuo Fengtongbao tablets are removed from the coating, finely ground, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is performed for 10 min, filtration is performed, the residue of the filtrate is dried by evaporation, 5 ml of ethyl acetate is added, ultrasonic treatment is performed for 5 min, centrifugation is performed, and the supernatant is taken as the Huatuo Fengtongbao tablet test solution;
[0011] (4) 2 g of Zanthoxylum nitidum (Roxb.) DC. medicinal material negative sample of Huatuo Fengtongbao tablets is finely ground, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is performed for 10 min, filtration is performed, the residue of the filtrate is dried by evaporation, 5 ml of ethyl acetate is added, ultrasonic treatment is performed for 5 min, centrifugation is performed, and the supernatant is taken as the Zanthoxylum nitidum (Roxb.) DC. medicinal material negative sample test solution of Huatuo Fengtongbao tablets;
[0012] (5) Take 10 Huatuo Fengtongbao capsules, take the contents, grind finely, take 0.75 g of fine powder, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, add 5 ml of ethyl acetate to the residue after evaporation of the filtrate, ultrasonic treatment for 5 min, centrifugation, take the supernatant as the Huatuo Fengtongbao capsule test solution, and reserve it;
[0013] (6) Take 2 g of negative sample of Huatuo Fengtongbao capsule without two-flank needle medicinal material, grind finely, take 0.75 g of fine powder, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, add 5 ml of ethyl acetate to the residue after evaporation of the filtrate, ultrasonic treatment for 5 min, centrifugation, take the supernatant as the Huatuo Fengtongbao capsule negative sample test solution without two-flank needle medicinal material;
[0014] (7) Take 10 two-flank needle analgesic tablets, remove the coating, grind finely, take 0.36 g of fine powder, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, add 5 ml of ethyl acetate to the residue after evaporation of the filtrate, ultrasonic treatment for 5 min, centrifugation, take the supernatant as the two-flank needle analgesic tablet test solution;
[0015] (8) Take 2 g of negative sample of two-flank needle analgesic tablet without two-flank needle medicinal material, grind finely, take 0.75 g of fine powder, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, add 5 ml of ethyl acetate to the residue after evaporation of the filtrate, ultrasonic treatment for 5 min, centrifugation, take the supernatant as the two-flank needle analgesic tablet negative sample test solution without two-flank needle medicinal material;
[0016] (9) Take 10 μl of each of the solutions in steps (1)-(8) respectively, and point them on the same silica gel G thin layer plate, adopt the upward development method, use petroleum ether-cyclohexane-ethyl acetate-glacial acetic acid with a volume ratio of 12:1:4:0.1 as the developing agent, develop, take out, naturally cool and dry, spray with sulfuric acid ethanol solution, place under ultraviolet light to observe, in the test product chromatogram, the test product chromatograms of steps (1), (3), (5), and (7) show the same color fluorescent spots at the corresponding positions of the two-flank needle control medicinal material chromatogram in step (2); the negative sample chromatograms of steps (2), (4), (6), and (8) have no corresponding fluorescent spots at the corresponding positions of the two-flank needle chromatogram in step (2).
[0017] Further, the silica gel G thin layer plate has a specification of 10 cm x 20 cm, and a coating thickness of 0.20-0.25 mm.
[0018] Further, the developing distance in step (9) is 11-12 cm.
[0019] Further, the petroleum ether in step (9) is petroleum ether (60-90).
[0020] Further, the sulfuric acid ethanol solution in step (9) is 10% sulfuric acid ethanol solution.
[0021] Further, the wavelength of the ultraviolet light lamp in the step (9) is 254 nm.
[0022] Further, in the step (9), the equilibrium time of the developing agent can be 25-35 min.
[0023] Further, in the step (9), the silica gel G thin layer plate is placed in an oven, the temperature is set to 35-45 DEG C, and is baked for 25-35 min, then the temperature is adjusted to 100-110 DEG C, and is baked for 5-8 min.
[0024] The present application has significant progress relative to the prior art:
[0025] The present application has the advantages that the two-flanked needle medicinal material and the two-flanked needle in the two-flanked needle analgesic tablet, Huatou Fengtongbao tablet and Huatou Fengtongbao capsule can be quickly identified; the respective test solution of the two-flanked needle medicinal material, the two-flanked needle analgesic tablet, the Huatou Fengtongbao tablet and the Huatou Fengtongbao capsule is spotted on the silica gel G thin layer plate, is developed, is taken out, is naturally dried, is placed under the ultraviolet light lamp and is observed; the test product chromatogram shows the same fluorescent spot at the position corresponding to the two-flanked needle chromatogram, the negative sample has no interference, the specificity and the repeatability are good. The method does not use the toxic chloroform, benzene and other organic solvents, is green and environment-friendly, the method is targeted to identify the fat-soluble effective part of the two-flanked needle and its preparation, is more in line with the requirement that the quality control method of traditional Chinese medicine must control the effective part or component in recent years, a unique and effective quality control method of the two-flanked needle and its preparation is established, and the development of the two-flanked needle medicinal material industry is promoted. BRIEF DESCRIPTION OF DRAWINGS
[0026] In order to more clearly illustrate the specific embodiments of the present application or the technical solutions in the prior art, the drawings needed to be used in the specific embodiments or the prior art description will be briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, the elements or parts are not necessarily drawn according to the actual proportions.
[0027] Figure 1 It is the two-flanked needle medicinal material thin layer chromatography identification chart of the present application, and the sample corresponding to the serial number in the identification chart is: 1 is the two-flanked needle control medicinal material solution, 2-4 are three batches of two-flanked needle medicinal material test product solutions;
[0028] Figure 2 It is the Huatou Fengtongbao tablet thin layer chromatography identification chart of the present application, and the sample corresponding to the serial number in the identification chart is: 1 is the two-flanked needle control medicinal material solution, 2 is the Huatou Fengtongbao tablet without two-flanked needle medicinal material negative sample solution, 3-5 are three batches of Huatou Fengtongbao tablet test product solutions;
[0029] Figure 3The identification chart of the two-faced needle analgesic tablet of the present application is shown in the table below. The sample corresponding to the serial number in the identification chart is as follows: 1 is the two-faced needle reference medicinal material solution, 2 is the two-faced needle analgesic tablet without the two-faced needle medicinal material negative sample solution, and 3-5 are three batches of the two-faced needle analgesic tablet test sample solutions.
[0030] Figure 4 The identification chart of the two-faced needle analgesic tablet of the present application is shown in the table below. The sample corresponding to the serial number in the identification chart is as follows: 1 is the two-faced needle reference medicinal material solution, 2 is the two-faced needle analgesic tablet without the two-faced needle medicinal material negative sample solution, and 3-5 are three batches of the two-faced needle analgesic tablet test sample solutions. DETAILED DESCRIPTION
[0031] In order for those skilled in the art to better understand the technical solutions in the present application, the technical solutions of the present application will be described clearly and completely below in conjunction with the accompanying drawings and embodiments. Obviously, the described embodiments are only a part of the embodiments of the present application, and all other embodiments obtained by those skilled in the art without creative labor based on the embodiments in the present application should belong to the scope of protection of the present application.
[0032] Example 1: Identification of two-faced needle medicinal material
[0033] (1) Take two-faced needle reference medicinal material 0.5 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, evaporate the residue of the filtrate to dryness, add 5 ml of ethyl acetate, ultrasonic treatment for 5 min, centrifuge, and take the supernatant as the two-faced needle reference medicinal material solution;
[0034] (2) Take two-faced needle medicinal material powder 0.5 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, evaporate the residue of the filtrate to dryness, add 5 ml of ethyl acetate, ultrasonic treatment for 5 min, centrifuge, and take the supernatant as the two-faced needle medicinal material test solution, a total of 3 batches of two-faced needle medicinal material test solution are prepared;
[0035] (3) Take 10 μl of each corresponding test solution in steps (1)-(2) respectively, and point them on the same silica gel G thin layer plate, using the upward development method, with a volume ratio of 12:1:4:0.1 of petroleum ether (60-90)-cyclohexane-ethyl acetate-glacial acetic acid as the developing agent, develop, take out, naturally cool and dry, spray with 10% sulfuric acid ethanol solution, and observe under ultraviolet light at 254 nm. As shown in the following table, the three batches of two-faced needle medicinal material test solution in step (2) all show the same color fluorescent spots at the corresponding positions of the two-faced needle reference medicinal material chromatogram. Figure 1
[0036] Example 2: Identification of Huatuo Fengtongbao tablet
[0037] (1) Take two needles for the control of medicinal materials 0.5 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, filter residue is added to ethyl acetate 5 ml, ultrasonic treatment for 5 min, centrifugal, take supernatant as two needles for the control of medicinal materials solution;
[0038] (2) Take Huatou Fengtongbao tablets 10 tablets, remove the coating, fine, take fine powder 0.75 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, filter residue is added to ethyl acetate 5 ml, ultrasonic treatment for 5 min, centrifugal, take supernatant as Huatou Fengtongbao tablets test solution; a total of 3 batches of Huatou Fengtongbao tablets test solution;
[0039] (3) Take Huatou Fengtongbao tablets lack of two needles medicinal negative sample 2 g, fine, take fine powder 0.75 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, filter residue is added to ethyl acetate 5 ml, ultrasonic treatment for 5 min, centrifugal, take supernatant as Huatou Fengtongbao tablets lack of two needles medicinal negative sample test solution;
[0040] (4) Take 10 μl of each of the solutions in steps (1)-(3) and point on the same silica gel G thin layer plate, using the upward development method, with a volume ratio of 12:1:4:0.1 of petroleum ether (60-90)-cyclohexane-ethyl acetate-glacial acetic acid as the developing agent, develop, take out, naturally cool and dry, spray with 10% sulfuric acid ethanol solution, and observe under ultraviolet light at 254 nm. As shown in the test, the test solution chromatogram of the three batches of Huatou Fengtongbao tablets in step (2) shows the same color fluorescent spots at the corresponding position of the two needles control medicinal chromatogram; the negative sample chromatogram in step (3) has no corresponding fluorescent spots at the corresponding position of the two needles control medicinal chromatogram. Figure 2
[0041] Example 3: Identification of Huatou Fengtongbao Capsules
[0042] (1) Take two needles for the control of medicinal materials 0.5 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, filter residue is added to ethyl acetate 5 ml, ultrasonic treatment for 5 min, centrifugal, take supernatant as two needles for the control of medicinal materials solution;
[0043] (2) Take Huatou Fengtongbao capsules 10 capsules, take the contents, fine, take fine powder 0.75 g, add 20 ml of anhydrous ethanol, ultrasonic treatment for 10 min, filter, filter residue is added to ethyl acetate 5 ml, ultrasonic treatment for 5 min, centrifugal, take supernatant as Huatou Fengtongbao capsules test solution; a total of 3 batches of Huatou Fengtongbao capsules test solution;
[0044] (3) Take 2g of negative sample of Zanthoxyli Folium from Hua Tuo Feng Tong Bao Capsules, grind finely, take 0.75g of fine powder, add 20ml of absolute ethanol, ultrasonic treatment for 10 minutes, filter, evaporate the filtrate, add 5ml of ethyl acetate to the residue, ultrasonic treatment for 5 minutes, centrifugal, take the supernatant as the negative sample solution of Zanthoxyli Folium from Hua Tuo Feng Tong Bao Capsules;
[0045] (4) Take 10μl of each solution in steps (1)-(3) respectively, and point on the same silica gel G thin layer plate, adopt upward development method, take petroleum ether (60-90)-cyclohexane-ethyl acetate-glacial acetic acid as developing agent with the volume ratio of 12:1:4:0.1, develop, take out, dry naturally, spray with 10% sulfuric acid ethanol solution, and observe under ultraviolet light 254nm, if the test sample chromatogram in step (2) shows the same color fluorescent spots as Zanthoxyli Folium control drug chromatogram in corresponding position, and step (3) negative sample chromatogram in corresponding position has no fluorescent spots. Figure 3
[0046] Example 4: Identification of Zanthoxyli Folium Analgesic Tablets
[0047] (1) Take 0.5g of Zanthoxyli Folium control drug, add 20ml of absolute ethanol, ultrasonic treatment for 10 minutes, filter, evaporate the filtrate, add 5ml of ethyl acetate to the residue, ultrasonic treatment for 5 minutes, centrifugal, take the supernatant as the solution of Zanthoxyli Folium control drug;
[0048] (2) Take 10 Zanthoxyli Folium Analgesic Tablets, remove the coating, grind finely, take 0.36g of fine powder, add 20ml of absolute ethanol, ultrasonic treatment for 10 minutes, filter, evaporate the filtrate, add 5ml of ethyl acetate to the residue, ultrasonic treatment for 5 minutes, centrifugal, take the supernatant as the test solution of Zanthoxyli Folium Analgesic Tablets; prepare 3 batches of test solution of Zanthoxyli Folium Analgesic Tablets;
[0049] (3) Take 2g of negative sample of Zanthoxyli Folium from Zanthoxyli Folium Analgesic Tablets, grind finely, take 0.75g of fine powder, add 20ml of absolute ethanol, ultrasonic treatment for 10 minutes, filter, evaporate the filtrate, add 5ml of ethyl acetate to the residue, ultrasonic treatment for 5 minutes, centrifugal, take the supernatant as the negative sample solution of Zanthoxyli Folium from Zanthoxyli Folium Analgesic Tablets;
[0050] (4) Take 10μl of each solution in steps (1)-(3) respectively, and point on the same silica gel G thin layer plate, adopt upward development method, take petroleum ether (60-90)-cyclohexane-ethyl acetate-glacial acetic acid as developing agent with the volume ratio of 12:1:4:0.1, develop, take out, dry naturally, spray with 10% sulfuric acid ethanol solution, and observe under ultraviolet light 254nm, if the test sample chromatogram in step (2) shows the same color fluorescent spots as Zanthoxyli Folium control drug chromatogram in corresponding position, and step (3) negative sample chromatogram in corresponding position has no fluorescent spots. Figure 4 As shown, the 3 batches of Zilanchi analgesic tablet test sample chromatograms in step (2) showed the same color fluorescent spots at the corresponding positions of Zilanchi control drug chromatogram; and the negative sample chromatogram in step (3) had no corresponding fluorescent spots at the corresponding positions of Zilanchi control drug chromatogram.
[0051] In the above examples, the silica gel G thin layer plate has a specification of 10 cm x 20 cm and a coating thickness of 0.20-0.25 mm.
[0052] In the above examples, the developing distance is 11-12 cm.
[0053] In the above examples, the equilibration time of the developing agent used can be 25-35 min. The equilibration time can be 25, 30 or 35 min, etc.
[0054] In the above examples, the treatment measures for the silica gel G thin layer plate are as follows:
[0055] The first treatment measure: the silica gel G thin layer plate is placed in an oven, the temperature is set to 35°C, and is baked for 25 min, then the temperature is adjusted to 100°C, and is baked for 5 min. The silica gel G thin layer plate is activated.
[0056] The second treatment measure: the silica gel G thin layer plate is placed in an oven, the temperature is set to 45°C, and is baked for 35 min, then the temperature is adjusted to 110°C, and is baked for 8 min. The silica gel G thin layer plate is activated.
[0057] The third treatment measure: the silica gel G thin layer plate is placed in an oven, the temperature is set to 40°C, and is baked for 30 min, then the temperature is adjusted to 105°C, and is baked for 6 min. The silica gel G thin layer plate is activated.
[0058] The fourth treatment measure: the silica gel G thin layer plate is placed in an oven, the temperature is set to 35°C, and is baked for 25 min, then the temperature is adjusted to 100°C, and is baked for 7 min. The silica gel G thin layer plate is activated.
[0059] After the above treatment of the silica gel G thin layer plate, the occurrence of plate cracking can be effectively prevented; and the internal pore structure of the silica gel can be changed to improve the separation efficiency of the silica gel plate. The occurrence rate of plate cracking is reduced, thereby improving the efficiency of identification work.
[0060] Obviously, the above examples are merely exemplary and are not intended to limit the embodiments. Based on the above description, other different forms of changes or variations can be made by those of ordinary skill in the art. All embodiments do not need to be exhaustively listed here. The obvious changes or variations derived therefrom are still within the protection scope of the present application.
Claims
1. A method for rapid identification of Radix Kadsurae and its preparations, characterized in that, The preparation is Huatou Fengtongbao tablet, Huatou Fengtongbao capsule and Zhen Tong tablet containing Zhen Tong medicine, and the method comprises the following steps: (1) 0.5 g of Zhen Tong medicine is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Zhen Tong medicine solution; (2) 0.5 g of Zhen Tong medicine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Zhen Tong medicine test solution; (3) 10 Huatou Fengtongbao tablets are taken, the coating is removed, fine grinding is conducted, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Huatou Fengtongbao tablet test solution; (4) 2 g of Huatou Fengtongbao tablet negative sample without Zhen Tong medicine is taken, fine grinding is conducted, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Huatou Fengtongbao tablet negative sample without Zhen Tong medicine test solution; (5) 10 Huatou Fengtongbao capsules are taken, the contents are taken, fine grinding is conducted, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Huatou Fengtongbao capsule test solution; (6) 2 g of Huatou Fengtongbao capsule negative sample without Zhen Tong medicine is taken, fine grinding is conducted, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Huatou Fengtongbao capsule negative sample without Zhen Tong medicine test solution; (7) 10 Zhen Tong tablet is taken, the coating is removed, fine grinding is conducted, 0.36 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Zhen Tong tablet test solution; (8) 2 g of Zhen Tong tablet negative sample without Zhen Tong medicine is taken, fine grinding is conducted, 0.75 g of fine powder is taken, 20 ml of anhydrous ethanol is added, ultrasonic treatment is conducted for 10 min, filtration is conducted, the filtrate is evaporated to dryness, 5 ml of ethyl acetate is added to the residue, ultrasonic treatment is conducted for 5 min, centrifugation is conducted, and the supernatant is taken as the Zhen Tong tablet negative sample without Zhen Tong medicine test solution; (9) Take 10 μl of each of the solutions obtained in steps (1) to (8) and spot them on the same silica gel G thin layer plate, and develop them by the ascending method using petroleum ether-cyclohexane-ethyl acetate-glacial acetic acid (12:1:4:0.1 by volume) as the developing agent. Take out the plate, dry naturally, spray with sulfuric acid ethanol solution, and examine under ultraviolet light. In the chromatogram of the test sample, the test sample chromatograms of steps (1), (3), (5), and (7) show the same colored fluorescent spots as the corresponding positions of the two-flanked needle control drug material chromatogram; the negative sample chromatograms of steps (4), (6), and (8) do not show the corresponding fluorescent spots as the two-flanked needle chromatogram; The developing distance in step (9) is 11-12 cm; In step (9), the equilibration time of the developing agent can be 25-35 min; In step (9), the silica gel G thin layer plate is placed in an oven, the temperature is set to 35-45 °C, and the plate is baked for 25-35 min, then the temperature is adjusted to 100-110 °C, and the plate is baked for 15-20 min.
2. The method according to claim 1, characterized in that: The silica gel G thin layer plate has a specification of 10 cm x 20 cm and a coating thickness of 0.20-0.25 mm.
3. The method according to claim 1, characterized in that: The petroleum ether in step (9) is petroleum ether (60-90).
4. The method according to claim 1, characterized in that: The sulfuric acid ethanol solution in step (9) is a 10% sulfuric acid ethanol solution.
5. The method according to claim 1, wherein the method is characterized by: The wavelength of the ultraviolet light in step (9) is 254 nm.
